285 related articles for article (PubMed ID: 18695685)
1. Epidermolysis bullosa: prospects for cell-based therapies.
Uitto J
J Invest Dermatol; 2008 Sep; 128(9):2140-2. PubMed ID: 18695685
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic cell therapy for epidermolysis bullosa.
Poocheron V; Hu S; Kirsner RS
J Invest Dermatol; 2008 Sep; 128(9):2134. PubMed ID: 18695682
[No Abstract] [Full Text] [Related]
3. Molecular pathology of the basement membrane zone in heritable blistering diseases:: The paradigm of epidermolysis bullosa.
Uitto J; Has C; Vahidnezhad H; Youssefian L; Bruckner-Tuderman L
Matrix Biol; 2017 Jan; 57-58():76-85. PubMed ID: 27496350
[TBL] [Abstract][Full Text] [Related]
4. Potential of fibroblast cell therapy for recessive dystrophic epidermolysis bullosa.
Wong T; Gammon L; Liu L; Mellerio JE; Dopping-Hepenstal PJ; Pacy J; Elia G; Jeffery R; Leigh IM; Navsaria H; McGrath JA
J Invest Dermatol; 2008 Sep; 128(9):2179-89. PubMed ID: 18385758
[TBL] [Abstract][Full Text] [Related]
5. Epidermolysis bullosa: Molecular pathology of connective tissue components in the cutaneous basement membrane zone.
Has C; Nyström A; Saeidian AH; Bruckner-Tuderman L; Uitto J
Matrix Biol; 2018 Oct; 71-72():313-329. PubMed ID: 29627521
[TBL] [Abstract][Full Text] [Related]
6. Treatment of hereditary epidermolysis bullosa: updates and future prospects.
Hsu CK; Wang SP; Lee JY; McGrath JA
Am J Clin Dermatol; 2014 Feb; 15(1):1-6. PubMed ID: 24402870
[TBL] [Abstract][Full Text] [Related]
7. Replenishment of type VII collagen and re-epithelialization of chronically ulcerated skin after intradermal administration of allogeneic mesenchymal stromal cells in two patients with recessive dystrophic epidermolysis bullosa.
Conget P; Rodriguez F; Kramer S; Allers C; Simon V; Palisson F; Gonzalez S; Yubero MJ
Cytotherapy; 2010 May; 12(3):429-31. PubMed ID: 20230217
[TBL] [Abstract][Full Text] [Related]
8. Inherited epidermolysis bullosa: past, present, and future.
Fine JD
Ann N Y Acad Sci; 2010 Apr; 1194():213-22. PubMed ID: 20536471
[TBL] [Abstract][Full Text] [Related]
9. Cell- and protein-based therapy approaches for epidermolysis bullosa.
Nyström A; Bruckner-Tuderman L; Kern JS
Methods Mol Biol; 2013; 961():425-40. PubMed ID: 23325662
[TBL] [Abstract][Full Text] [Related]
10. Pretibial epidermolysis bullosa: is this case a new subtype with loss of types IV and VII collagen?
Lee HS; Park K; Son SJ; Song KY; Kim SE
Int J Dermatol; 2009 Aug; 48(8):879-81. PubMed ID: 19659868
[TBL] [Abstract][Full Text] [Related]
11. Dual mechanism of type VII collagen transfer by bone marrow mesenchymal stem cell extracellular vesicles to recessive dystrophic epidermolysis bullosa fibroblasts.
McBride JD; Rodriguez-Menocal L; Candanedo A; Guzman W; Garcia-Contreras M; Badiavas EV
Biochimie; 2018 Dec; 155():50-58. PubMed ID: 29653141
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of fibroblast cell therapy for dystrophic epidermolysis bullosa: high stability of collagen VII favors long-term skin integrity.
Kern JS; Loeckermann S; Fritsch A; Hausser I; Roth W; Magin TM; Mack C; Müller ML; Paul O; Ruther P; Bruckner-Tuderman L
Mol Ther; 2009 Sep; 17(9):1605-15. PubMed ID: 19568221
[TBL] [Abstract][Full Text] [Related]
13. The long and winding road that leads to a cure for epidermolysis bullosa.
Carulli S; Contin R; De Rosa L; Pellegrini G; De Luca M
Regen Med; 2013 Jul; 8(4):467-81. PubMed ID: 23826700
[TBL] [Abstract][Full Text] [Related]
14. Normal and gene-corrected dystrophic epidermolysis bullosa fibroblasts alone can produce type VII collagen at the basement membrane zone.
Woodley DT; Krueger GG; Jorgensen CM; Fairley JA; Atha T; Huang Y; Chan L; Keene DR; Chen M
J Invest Dermatol; 2003 Nov; 121(5):1021-8. PubMed ID: 14708601
[TBL] [Abstract][Full Text] [Related]
15. Disorders of the cutaneous basement membrane zone--the paradigm of epidermolysis bullosa.
Bruckner-Tuderman L; Has C
Matrix Biol; 2014 Jan; 33():29-34. PubMed ID: 23917088
[TBL] [Abstract][Full Text] [Related]
16. Anchoring fibrils and type VII collagen are absent from skin in severe recessive dystrophic epidermolysis bullosa.
Bruckner-Tuderman L; Mitsuhashi Y; Schnyder UW; Bruckner P
J Invest Dermatol; 1989 Jul; 93(1):3-9. PubMed ID: 2746005
[TBL] [Abstract][Full Text] [Related]
17. A phase II randomized vehicle-controlled trial of intradermal allogeneic fibroblasts for recessive dystrophic epidermolysis bullosa.
Venugopal SS; Yan W; Frew JW; Cohn HI; Rhodes LM; Tran K; Melbourne W; Nelson JA; Sturm M; Fogarty J; Marinkovich MP; Igawa S; Ishida-Yamamoto A; Murrell DF
J Am Acad Dermatol; 2013 Dec; 69(6):898-908.e7. PubMed ID: 24075228
[TBL] [Abstract][Full Text] [Related]
18. Gene Therapy for Epidermolysis Bullosa.
Marinkovich MP; Tang JY
J Invest Dermatol; 2019 Jun; 139(6):1221-1226. PubMed ID: 31068252
[TBL] [Abstract][Full Text] [Related]
19. New glycine substitution mutations in type VII collagen underlying epidermolysis bullosa pruriginosa but the phenotype is not explained by a common polymorphism in the matrix metalloproteinase-1 gene promoter.
Almaani N; Liu L; Harrison N; Tanaka A; Lai-Cheong J; Mellerio JE; McGrath JA
Acta Derm Venereol; 2009; 89(1):6-11. PubMed ID: 19197535
[TBL] [Abstract][Full Text] [Related]
20. Reduced Toxicity Conditioning and Allogeneic Hematopoietic Progenitor Cell Transplantation for Recessive Dystrophic Epidermolysis Bullosa.
Geyer MB; Radhakrishnan K; Giller R; Umegaki N; Harel S; Kiuru M; Morel KD; LeBoeuf N; Kandel J; Bruckner A; Fabricatore S; Chen M; Woodley D; McGrath J; Baxter-Lowe L; Uitto J; Christiano AM; Cairo MS
J Pediatr; 2015 Sep; 167(3):765-9.e1. PubMed ID: 26148662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
